Stock listing

Beam Therapeutics Inc.

Selected listing: BEAM · NASDAQ · USD · US

Beam Therapeutics Inc. (NASDAQ:BEAM), Health Technology. Latest release Sep 8, 2026: Beam Therapeutics Presents Updated Clinical Data from the Phase 1/2 Trial…

BEAM:NASDAQUSDUSUpdated September 25, 2026

Ticker: NASDAQ:BEAM
Asset type: Stock
Sector: Health Technology
Industry: Biotechnology
Exchange: NASDAQ
Currency: USD

About Beam Therapeutics Inc.

Beam Therapeutics Inc. is a public company traded under the ticker BEAM in the American market. Beam Therapeutics focuses on developing precision genetic medicines to treat various diseases.

Latest news from Beam Therapeutics Inc.

Beam Therapeutics Presents Updated Clinical Data from the Phase 1/2 Trial of BEAM-302 in Alpha-1 Antitrypsin Deficiency (AATD) at the European Respiratory Society (ERS) Congress 2026

September 8, 2026

Beam Therapeutics Appoints Eric Foster as Chief Commercial Officer

September 1, 2026

Beam Therapeutics to Participate in Upcoming September 2026 Investor Conferences

August 31, 2026

Beam Therapeutics Reports Second Quarter 2026 Financial Results and Announces First Patient Dosed in Global Pivotal Cohort of BEAM-302 Trial in Alpha-1 Antitrypsin Deficiency (AATD)

August 4, 2026

Beam Therapeutics to Present Updated Data from Phase 1/2 Trial of BEAM-302 in Alpha-1 Antitrypsin Deficiency (AATD) in Late-Breaking Oral Presentation at the European Respiratory Society (ERS) Congress 2026

July 23, 2026

All Beam Therapeutics Inc. news →

Events

Replays

Beam Therapeutics Inc. (BEAM) Q4 2025 Earnings Call
Tue, Feb 24, 2026 · 08:00 AM ET
Watch
Beam Therapeutics Inc. (BEAM) Q3 2024 Earnings Call
Tue, Nov 05, 2024 · 08:30 AM ET
Watch